Intuitive Surgical stock (US46120E6023): Drops 6% to 52-week low on FDA recall concerns

Intuitive Surgical shares plunged 6.6% to a 52-week low of $417.80 on May 11, 2026, amid an FDA Class I recall for staplers linked to injuries and institutional selling pressure.

Intuitive Surgical, Inc. shares tumbled 6.6% on Monday, May 11, 2026, hitting a fresh 52-week low of $417.80 during Nasdaq trading, according to ts2.tech as of 05/11/2026. The decline followed reports of an FDA Class I recall for 8mm SureForm 30 Gray Reload staplers used with the da Vinci system, due to incomplete staple lines associated with serious injuries and one death, as noted in TradingKey as of 05/11/2026. The stock closed at $420.22, underperforming the iShares U.S. Medical Devices ETF's 3% drop.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intuitive Surgical, Inc.
• Sector/industry: Medical Devices / Robotic Surgery
• Headquarters/country: United States
• Core markets: US, Europe, Asia
• Key revenue drivers: da Vinci surgical systems, instruments, services
• Home exchange/listing venue: Nasdaq (ISRG)
• Trading currency: USD

Intuitive Surgical, Inc.: core business model

Intuitive Surgical, Inc. pioneered robotic-assisted minimally invasive surgery with its da Vinci Surgical System, which dominates the global market for such technology. The company develops, manufactures, and sells these systems, along with related instruments and accessories, generating recurring revenue from procedures and services. As a leader in the US medtech sector, it benefits from strong adoption in hospitals serving American patients.

The business model relies on an installed base of over 8,000 da Vinci systems worldwide as of recent filings, driving high-margin consumables sales. Services and maintenance contracts further bolster margins, reported at 28.15% net margin for Q1 2026 published April 21, 2026, per MarketBeat as of 05/11/2026.

Main revenue and product drivers for Intuitive Surgical, Inc.

Primary revenue comes from da Vinci system placements, instruments used in procedures, and service contracts. Q1 2026 revenue reached $2.77 billion, up 23% year-over-year, beating estimates of $2.62 billion, with EPS of $2.50 versus $2.08 expected, according to data published April 21, 2026, on MarketBeat as of 05/11/2026. Procedure growth remains a key driver, particularly in the US market.

Instruments and accessories account for the majority of sales due to per-procedure usage, while new system sales target expansions in general surgery and emerging applications. Institutional investors have trimmed stakes amid valuation concerns, as reported in recent filings.

Industry trends and competitive position

The robotic surgery market is expanding, with US demand fueled by aging demographics and preference for minimally invasive procedures. Intuitive Surgical holds over 80% global market share, but faces competition from Medtronic and Johnson & Johnson. Its da Vinci Xi and SP platforms continue to innovate for US hospitals.

Why Intuitive Surgical, Inc. matters for US investors

Listed on Nasdaq, Intuitive Surgical offers US investors exposure to medtech innovation critical to American healthcare. With a market cap of $159.39 billion and strong US revenue exposure, it aligns with growth in elective surgeries post-pandemic, despite regulatory hurdles.

Conclusion

Intuitive Surgical, Inc. faces near-term pressure from the FDA stapler recall and institutional selling, driving shares to a 52-week low on May 11, 2026. Strong Q1 results with 23% revenue growth highlight operational strength, while high valuation and regulatory risks weigh on sentiment. US investors track its dominance in robotic surgery amid evolving medtech trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.